Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
BIIB

BIIB - Biogen Inc Stock Price, Fair Value and News

220.12USD+0.81 (+0.37%)Delayed as of 18 Mar 2024, 01:59 pm ET

Market Summary

BIIB
USD220.12+0.81
Delayedas of 18 Mar 2024, 01:59 pm
0.37%

BIIB Alerts

  • 1 major insider buys and 1 major insider sales recently.
  • Big fall in earnings (Y/Y)

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

31.9B

Price/Earnings (Trailing)

27.46

Price/Sales (Trailing)

3.24

EV/EBITDA

18.45

Price/Free Cashflow

25.1

BIIB Price/Sales (Trailing)

BIIB Profitability

Operating Margin

94.45%

EBT Margin

13.18%

Return on Equity

7.85%

Return on Assets

4.33%

Free Cashflow Yield

3.98%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

9.8B

Rev. Growth (Yr)

-6.2%

Rev. Growth (Qtr)

-5.69%

BIIB Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

-54.63%

Earnings Growth (Qtr)

466.67%

Breaking Down BIIB Revenue

52 Week Range

218.10319.76
(Low)(High)

Last 7 days

-9.1%

Last 30 days

-11.7%

Last 90 days

-3.9%

Trailing 12 Months

-23.5%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

2

Debt/Equity

0.47

Debt/Cashflow

0.22

BIIB Investor Care

Shares Dilution (1Y)

0.61%

Diluted EPS (TTM)

7.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202310.1B10.0B10.0B9.8B
202210.8B10.6B10.4B10.2B
202112.6B11.7B11.1B11.0B
202014.4B14.5B14.3B13.4B
201913.8B14.1B14.2B14.4B
201812.6B12.9B13.2B13.5B
201711.5B11.7B11.8B12.3B
201610.9B11.2B11.4B11.4B
201510.1B10.3B10.6B10.8B
20147.6B8.3B9.0B9.7B
20135.6B5.9B6.4B6.9B
20125.1B5.3B5.4B5.5B
20114.8B4.8B4.9B5.0B
20104.4B4.6B4.6B4.7B
20094.2B4.3B4.3B4.4B
200803.5B3.8B4.1B
20070003.2B

Tracking the Latest Insider Buys and Sells of Biogen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 22, 2024
singhal priya
sold
-57,962
221
-262
head of development
Feb 16, 2024
izzar rachid
acquired
-
-
2,017
head of global product strat.
Feb 16, 2024
kramer robin
sold (taxes)
-86,755
219
-396
chief accounting officer
Feb 16, 2024
gregory ginger
sold (taxes)
-495,997
219
-2,264
evp, human resources
Feb 16, 2024
singhal priya
sold (taxes)
-102,529
219
-468
head of development
Feb 16, 2024
mcdonnell michael r
acquired
-
-
6,720
evp, chief financial officer
Feb 16, 2024
alexander susan h
sold (taxes)
-533,898
219
-2,437
evp chief legal officer
Feb 16, 2024
izzar rachid
sold (taxes)
-208,564
219
-952
head of global product strat.
Feb 16, 2024
murphy nicole
sold (taxes)
-133,639
219
-610
head of pharm ops and tech
Feb 16, 2024
singhal priya
acquired
-
-
1,208
head of development

1–10 of 50

Which funds bought or sold BIIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 14, 2024
Leo Wealth, LLC
new
-
2,264,860
2,264,860
0.23%
Mar 12, 2024
ROVIN CAPITAL /UT/ /ADV
added
30.34
127,000
534,000
0.24%
Mar 11, 2024
VANGUARD GROUP INC
added
18.2
595,596,000
3,728,180,000
0.08%
Mar 11, 2024
Wahed Invest LLC
added
6.46
41,756
622,342
0.17%
Mar 08, 2024
TRUST CO OF VERMONT
reduced
-3.26
-15,158
567,741
0.04%
Mar 07, 2024
Brown Shipley& Co Ltd
reduced
-69.81
-130,899
57,188
0.03%
Mar 06, 2024
SageView Advisory Group, LLC
added
8.19
9,061
234,973
0.01%
Mar 05, 2024
Fisher Asset Management, LLC
reduced
-43.96
-12,743,600
16,504,000
0.01%
Mar 05, 2024
GREENWOOD CAPITAL ASSOCIATES LLC
added
100
5,004,540
9,908,300
0.64%
Mar 04, 2024
Fortis Group Advisors, LLC
added
100
3,909
7,764
-%

1–10 of 48

Are Funds Buying or Selling BIIB?

Are funds buying BIIB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIIB
No. of Funds

Unveiling Biogen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
primecap management co/ca/
11.22%
16,264,481
SC 13G/A
Feb 12, 2024
vanguard group inc
10.02%
14,521,342
SC 13G/A
Feb 12, 2024
vanguard group inc
9.94%
14,406,879
SC 13G/A
Jan 24, 2024
blackrock inc.
9.8%
14,246,320
SC 13G/A
Feb 09, 2023
primecap management co/ca/
10.9%
15,700,576
SC 13G/A
Feb 09, 2023
vanguard group inc
8.32%
11,976,623
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
14,260,137
SC 13G/A
Mar 07, 2022
blackrock inc.
9.4%
13,736,954
SC 13G/A
Feb 10, 2022
primecap management co/ca/
10.73%
15,757,405
SC 13G/A
Feb 09, 2022
vanguard group inc
7.85%
11,537,299
SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings
Date Filed Form Type Document
Feb 26, 2024
4
Insider Trading
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of BIIB?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Biogen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
381.0B
93.0B
-3.60% -2.76%
10.84
4.47
6.46% 95.94%
307.8B
60.1B
7.72% 18.52%
843.2
5.12
1.40% -97.49%
157.8B
46.5B
-3.76% -37.06%
-113.63
3.39
42.59% -114.62%
144.1B
28.2B
-7.44% 18.02%
21.45
5.11
7.09% 2.52%
91.8B
27.1B
-17.13% -16.65%
16.21
3.39
-0.60% 23.36%
15.0B
15.8B
15.02% 26.90%
-26.11
0.95
6.17% 76.47%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.5
2.89
49.61% 324.78%
4.1B
4.7B
-2.94% -9.06%
-324.06
0.88
4.58% 90.97%
3.4B
8.8B
-0.23% 18.85%
-5.68
0.38
7.79% -163.11%
2.1B
644.4M
-0.28% 70.16%
15.05
3.21
29.14% 50.51%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.9
1.83
16.26% -147.49%
25.4M
70.0M
-0.88% -54.80%
0.37
0.34
-19.54% 888.31%
19.9M
-
58.23% -28.98%
-1.08
0.22
2882.68% -138.52%
15.4M
111.1M
-6.33% -18.68%
-0.97
0.14
-10.43% 84.90%
1.4M
20.0M
-35.83% -91.10%
-0.1
0.07
137.71% 66.04%

Biogen Inc News

Latest updates
MarketBeat • 5 hours ago
Yahoo Movies Canada • 28 hours ago
MarketWatch • 15 Mar 2024 • 10:01 pm
Defense World • 15 Mar 2024 • 09:29 am
Yahoo Finance • 14 Mar 2024 • 03:30 pm
MarketWatch • 12 Mar 2024 • 10:00 pm

Biogen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-5.7%2,3862,5302,4562,4632,5442,5092,5892,5322,7342,7792,7752,6942,8533,3763,6823,5343,6713,6003,6173,4903,526
Costs and Expenses-21.6%2,0952,6721,7482,0251,9401,1371,3202,1842,5822,4882,1931,7202,6862,2901,7071,7141,8941,7941,6611,9872,083
  S&GA Expenses-22.8%609788548605633563573635788654637595806573555570665555588568591
EBITDA Margin-10.5%0.21*0.23*0.38*0.44*0.43*0.40*0.29*0.22*0.23*0.21*0.26*0.36*---------
Interest Expenses12.1%72.0064.0049.0063.0055.0060.0066.0066.0066.0066.0056.0065.0056.0056.0066.0044.0046.0046.0048.0048.0049.00
Income Taxes158.6%43.00-72.9011551.0054.00236217126443-25.90-40944.0013.00241446292276211248423470
Earnings Before Taxes306.5%292-1417084386041,3711,2703474052915824673539582,0381,6991,7281,7791,7591,8601,415
EBT Margin-18.1%0.13*0.16*0.31*0.36*0.35*0.33*0.22*0.15*0.16*0.15*0.20*0.30*---------
Net Income466.7%250-68.105923885501,1351,0583043683294494103587021,5421,3991,4401,5461,4941,409947
Net Income Margin-19.3%0.12*0.15*0.27*0.31*0.30*0.28*0.19*0.13*0.14*0.14*0.16*0.24*---------
Free Cashflow-110.2%-52.70518416389-2616027001047877631,155676---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-4.8%26,84528,19325,15724,59824,55424,85425,08123,61423,87723,80724,47023,85524,61924,93425,51226,11927,23427,48426,28826,44625,289
  Current Assets-18.9%6,8598,45410,4329,7639,7919,7669,7417,9167,8577,1627,1846,7206,8877,8438,4948,0078,3828,4487,9108,9437,641
    Cash Equivalents-54.1%1,0502,2882,6182,8983,4193,6762,6471,7492,2611,5421,7421,2181,3312,2252,3852,5912,9142,3441,7232,2431,225
  Inventory-15.3%2,5272,9821,3341,2811,3441,3751,2941,2151,3521,3481,2551,1721,0691,028953859804752777770930
  Net PPE0.2%3,3103,3023,3073,3013,2993,2663,3553,3733,4163,4113,4423,4383,4123,3603,3313,2823,2473,1383,0783,0143,601
  Goodwill1238.9%6,2194655,7545,7525,7495,7415,7505,7585,7615,7615,7645,7635,7625,7565,7515,7525,7585,7465,7495,6405,706
Liabilities-12.2%12,04513,71410,69610,81111,16612,08713,21812,39412,91812,92513,25613,19213,93314,19014,22313,58213,89513,49213,33912,62412,257
  Current Liabilities-31.6%3,4345,0223,1873,0153,2733,9265,0183,9474,2984,2123,3473,1663,7423,8043,4474,6394,8644,4323,2113,1493,295
  Long Term Debt-100.0%-6,7866,2856,2836,2816,2796,2776,2766,2746,2727,2697,2677,4267,4257,4244,4604,4594,4585,9495,9435,937
Shareholder's Equity2.2%14,79914,48414,46113,78713,39812,76711,86311,22110,96010,88211,21510,66310,68610,74511,28912,53713,33913,99212,94913,82213,032
  Retained Earnings1.4%17,62817,37817,44616,85416,46715,91614,96014,21613,91213,54413,90113,83413,97613,96114,46715,67316,45517,06516,18317,02716,257
  Additional Paid-In Capital24.9%30324217191.0073.00--11968.00------0.00-----
Shares Outstanding0.1%145145145144144144147147147150151152---------
Minority Interest100.0%--4.10-6.40-9.60-9.50-8.70-9.10-21.6064.00452463-19.00-14.20-14.00-19.50-10.00-4.10-4.10-4.10-7.90-8.00
Float---41,191---29,398---51,265---42,103---43,010--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-97.9%13.00592487455-1756617371628388051,227769-3671,1811,9491,4671,9601,6951,9641,4601,895
  Share Based Compensation395.1%191-64.80-74.1076.00189-65.70-58.0068.00170-57.60-55.8070.00132-35.40-49.5068.00139-47.80-55.0046.0035.00
Cashflow From Investing62.6%-652-1,742-753-953-1411,672694-648-112-233-152-64.70-166-52.40-832443708-365-110239-1,625
Cashflow From Financing-176.1%-646849-9.80-43.40-7.40-1,251-471-16.5010.00-746-564-785-401-1,312-1,313-2,245-2,116-689-2,375-679-1,437
  Buy Backs------250500--7504506004001,2502,8092,2202,0937182,4026561,353

BIIB Income Statement

2023-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues$ 9,835.6$ 10,173.4$ 10,981.7
Cost and expense:   
Cost of sales, excluding amortization and impairment of acquired intangible assets2,533.42,278.32,109.7
Research and development2,462.02,231.12,501.2
Selling, general and administrative2,549.72,403.62,674.3
Amortization and impairment of acquired intangible assets240.6365.9881.3
Collaboration profit sharing/(loss reimbursement)218.8(7.4)7.2
(Gain) loss on fair value remeasurement of contingent consideration0.0(209.1)(50.7)
Acquired in-process research and development0.00.018.0
Restructuring charges218.8131.10.0
Gain on sale of building0.0(503.7)0.0
Other (income) expense, net315.5(108.2)1,095.5
Total cost and expense8,538.86,581.69,236.5
Income before income tax (benefit) expense and equity in loss of investee, net of tax1,296.83,591.81,745.2
Income tax (benefit) expense135.3632.852.5
Equity in (income) loss of investee, net of tax0.0(2.6)(34.9)
Net income1,161.52,961.61,727.6
Net income (loss) attributable to noncontrolling interests, net of tax0.4(85.3)171.5
Net income attributable to Biogen Inc.$ 1,161.1$ 3,046.9$ 1,556.1
Net income per share:   
Basic earnings per share attributable to Biogen Inc. (in dollars per share)$ 8.02$ 20.96$ 10.44
Diluted earnings per share attributable to Biogen Inc. (in dollars per share)$ 7.97$ 20.87$ 10.40
Weighted-average shares used in calculating:   
Weighted average number of common shares outstanding (in shares)144,700145,300149,100
Diluted earnings per share attributable to Biogen Inc. (in shares)145,600146,000149,600
Product revenue, net   
Revenues$ 7,246.7$ 7,987.8$ 8,846.9
Revenue from anti-CD20 therapeutic programs   
Revenues1,689.61,700.51,658.5
Contract manufacturing, royalty and other revenue   
Revenues$ 899.3$ 485.1$ 476.3

BIIB Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,049.9$ 3,419.3
Marketable securities0.01,473.5
Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.3, respectively1,664.11,705.0
Due from anti-CD20 therapeutic programs435.9431.4
Inventory2,527.41,344.4
Other current assets1,182.01,417.6
Total current assets6,859.39,791.2
Marketable securities0.0705.7
Property, plant and equipment, net3,309.73,298.6
Operating lease assets420.0403.9
Intangible assets, net8,363.01,850.1
Goodwill6,219.25,749.0
Deferred tax asset928.61,226.4
Investments and other assets745.01,529.2
Total assets26,844.824,554.1
Current liabilities:  
Current portion of term loan150.00.0
Taxes payable257.4259.9
Accounts payable403.3491.5
Accrued expense and other2,623.62,521.4
Total current liabilities3,434.33,272.8
Notes payable and term loan6,788.26,281.0
Deferred tax liability641.8334.7
Long-term operating lease liabilities400.0333.0
Other long-term liabilities781.1944.2
Total liabilities12,045.411,165.7
Commitments, contingencies and guarantees (Notes 22 and 23)
Biogen Inc. shareholders’ equity  
Preferred stock, par value $0.001 per share0.00.0
Common stock, par value $0.0005 per share0.10.1
Additional paid-in capital302.573.3
Accumulated other comprehensive income (loss)(153.7)(164.9)
Retained earnings17,627.616,466.5
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively(2,977.1)(2,977.1)
Total Biogen Inc. shareholders’ equity14,799.413,397.9
Noncontrolling interests0.0(9.5)
Total equity14,799.413,388.4
Total liabilities and equity$ 26,844.8$ 24,554.1
BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.biogen.com
 EMPLOYEES8725

Biogen Inc Frequently Asked Questions


What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Fri Mar 15 2024, market cap of Biogen Inc is 31.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 15 2024, BIIB's PE ratio (Price to Earnings) is 27.46 and Price to Sales (PS) ratio is 3.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.032 (multiply by 100 for percentage) rate of return.